United States:
Development Of Substituted Pyrido[3,2-D]Pyrimidines As Potent And Selective Dihydrofolate Reductase Inhibitors For Pneumocystis Pneumonia Infection
29 July 2019
Kramer Levin Naftalis & Frankel LLP
To print this article, all you need is to be registered or login on Mondaq.com.
Intellectual Property scientific advisor Khushbu Shah
co-authored an article titled "Development of Substituted
Pyrido[3,2-d]Pyrimidines as Potent and Selective Dihydrofolate
Reductase Inhibitors for Pneumocystis Pneumonia Infection"
which was published in ScienceDirect on June 4, 2019. The article
discusses efforts to develop novel compounds that can provide safer
treatment for pneumocystis pneumonia infection.
The content of this article is intended to provide a general
guide to the subject matter. Specialist advice should be sought
about your specific circumstances.
POPULAR ARTICLES ON: Food, Drugs, Healthcare, Life Sciences from United States
FDA Ramps Up Actions On PFAS
Holland & Knight
The U.S. Food and Drug Administration (FDA) has increased regulatory activity with regard to per- and polyfluoroalkyl substances (PFAS).
Planning For The BIOSECURE Act
Foley Hoag LLP
Bipartisan legislation moving through the U.S. House and Senate, known as the BIOSECURE Act, could limit the ability of U.S. life sciences companies...
